The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection.
【저자키워드】 SARS-CoV, hypoxia inducible factor, roxadustat, vadadustat, adaptaquin, neuradapt, 【초록키워드】 COVID-19, Treatment, Ferroptosis, Anti-inflammatory, hypoxia, furin, Infection, viral entry, COVID-19 complications, erythropoiesis, inhibitor, moderate, boost, Analysis, recombinant, target gene, Stage, Severe case, problem, PhD, vessel, initial, significantly, addition, unlikely, activate, reveal, implicated, activating, treatment for COVID-19, 【제목키워드】 COVID-19, hydroxylase, Pro,